Monday, June 2, 2014

24-h Arteriograph ® Central BP

4. Laboratory investigations (WP4): fasting plasma glucose, lipids, serum creatinine, serum

liver enzymes, biomarkers (for inflammation, copeptin, etc., see Table 1), urinary spot sample

for microalbuminuria and albumin/creatinine ratio. In addition, faeces samples will be

obtained for determination of secreted factors as well as a genetic screening for evaluation of

the gut bacterial content and composition (microbiota). A biobank will be established in

technical collaboration between Lund University and other partners (Region Skåne,

BBMRI.se). Assessment of leukocyte types and activation in whole blood will be performed

in representative subsets of subjects.

5. Metabolic investigation (WP5): including fasting blood sampling for plasma glucose and

serum lipids (total cholesterol: C, HDL-C, LDL-C and triglycerides, LpLA2, Lp(a), etc.), and

an oral glucose tolerance test (OGTT; 75 g glucose), with measurements at 0,30,(60) and 120

min of plasma glucose, incretins (GLP-1, GIP), insulin, C-peptide and glucagon.

6. Technical investigations (WP6): arterial stiffness (Sphygmocor ® assessment of pulse wave

velocity, augmentation index, central blood pressure), arteria carotis morphology and

function (Sekoya ® ultrasound device), 24-h ambulatory blood pressure recordings, and

central aortic pressure (24-h Arteriograph ® Central BP). We will perform screening

spirometry and evaluation of endothelial function (by EndoPat ®).Measurement of Advanced

Glycation End Products (AGE) will be conducted transdermally by use of an AGE-Reader®.

In addition, other investigations are optional and depending on funding, such as brain

magnetic resonance imaging (MRI) as well as echocardiography, and retinal artery imaging

No comments: